Jinming Gu
Executive Director
Shanghai Hengrui Pharmaceutical
China
Biography
Dr. Jinming Gu obtained his Ph.D. degree in Molecular Biology from Vanderbilt University. He then joined Dana-Farber Cancer Institute/Harvard Medical School for a postdoctoral training in oncology. Dr. Gu started his industry career at Merrimack Pharmaceutical, Inc., where he worked on MM111, a bispecific antibody currently in Phase 2 clinical trial. He then joined Abbott Laboratories. Since joining Abbott/Abbvie, he has been leading/working on multiple mAb, ADC, and bispecific antibody programs, including ABT-806, ABT-414, and ABT-165 etc. Dr. Gu is currently the Executive Director of Biologics Discovery at Shanghai Hengrui Pharmaceutical Co., Ltd., a leading innovative pharmaceutical company in China.
Research Interest
Research Interest: Pharmaceutical R&D; Biologics Drug Discovery and Development, Cancer Immunotherapy, Biosimilar, Biobetter.